Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.

ABSTRACT: Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including fecal microbiota transplantation (FMT). This paper explores the recent approval of Vowst, a novel oral FMT drug, by the United States Food and Drug Administration (FDA) as a prophylactic therapy to prevent recurrent CDIs. Vowst comprises a formulation of live fecal microbiota spores and works by reestablishing the disrupted gut microbiota, limiting C. difficile spore germination, and promoting microbiome repair. Furthermore, this paper will discuss the product's approval journey and the uncertain

SUBMITTER: Jain N 

PROVIDER: S-EPMC10337487 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature